Trial report in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 4 institutions in 1 country.
Julia E BrittainVascular Biology Center, Augusta University, Augusta, Georgia.ORCID 0000-0003-1007-9210
Ciprian AneaVascular Biology Center, Augusta University, Augusta, Georgia.
Payal DesaiDivision of Hematology, Department of Medicine, The Ohio State University, Chapel Hill, North Carolina.
Jack DelaneyDivision of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Adam McDonaldDivision of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Stephen W LooneyDepartment of Biostatistics and Epidemiology, Augusta University, Augusta, Georgia.
Nigel S KeyDivision of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Leslie V PariseDepartment of Biochemistry & Biophysics, University of North Carolina, Chapel Hill, North Carolina.
Kenneth I AtagaDivision of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
University of North Carolina at Chapel Hill · USAugusta University Health · USAugusta University · USThe Ohio State University · US
Funding
Red Blood Cell Pathology in Hemodialysis PatientsR01DK093734 · NIDDK · AUGUSTA UNIVERSITY · PI BRITTAIN, JULIA · 2012 to 2016
$1.6M
A novel mechanism of coagulation in sickle cell diseaseR21HL102635 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRITTAIN, JULIA · 2011 to 2012
$393k
Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell DiseaseR21HL091265 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ATAGA, KENNETH I · 2008 to 2009
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. · full record | OpenQuestion